-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Introduction On September 14, 2020, BMJ (impact factor 30.
223) released a review aimed at exploring the pathophysiology, diagnosis, and management of hepatorenal syndrome.
This article intercepts some of the content and shares with you.
Management of Hepatorenal Syndrome.
This review summarizes the recommendations for the management of hepatorenal syndrome from the American Society for the Study of Liver Diseases (AASLD) and the European Society for the Study of the Liver (EASL), published by AASLD and EASL on patients with ascites and decompensated cirrhosis Related content is included in the management guide (Table 1).
The two guidelines differ in the choice of drug treatment for hepatorenal syndrome.
According to the EASL guidelines, terlipressin plus albumin should be the first-line treatment option for hepatorenal syndrome-acute kidney injury; however, according to the AASLD guidelines, the treatment options for hepatorenal syndrome-acute kidney injury are limited to albumin, octreotide plus Midodrine or norepinephrine.
Table 1 Recommendations for management of hepatorenal syndrome AKI: acute kidney injury; CKD: chronic kidney disease; CVP: central venous pressure; HRS: hepatorenal syndrome; ICU: intensive care unit; LT: liver transplantation; NAKI: non-acute kidney Injury; RRT: renal replacement therapy; SBP: spontaneous bacterial peritonitis; SCr: serum creatinine; TIPS: transjugular intrahepatic portosystemic shunt.
Literature index: Simonetto DA, Gines P, Kamath PS.
Hepatorenal syndrome: pathophysiology, diagnosis, and management.
BMJ.
2020 09 14;370.
doi: 10.
1136/bmj.
m2687.
●The most complete summary: Diagnosis and diagnosis of hepatorenal syndrome Treatment|Clinical Essentials ●Hepatorenal Syndrome: Why can kidney failure be caused by the absence of kidney disease?
223) released a review aimed at exploring the pathophysiology, diagnosis, and management of hepatorenal syndrome.
This article intercepts some of the content and shares with you.
Management of Hepatorenal Syndrome.
This review summarizes the recommendations for the management of hepatorenal syndrome from the American Society for the Study of Liver Diseases (AASLD) and the European Society for the Study of the Liver (EASL), published by AASLD and EASL on patients with ascites and decompensated cirrhosis Related content is included in the management guide (Table 1).
The two guidelines differ in the choice of drug treatment for hepatorenal syndrome.
According to the EASL guidelines, terlipressin plus albumin should be the first-line treatment option for hepatorenal syndrome-acute kidney injury; however, according to the AASLD guidelines, the treatment options for hepatorenal syndrome-acute kidney injury are limited to albumin, octreotide plus Midodrine or norepinephrine.
Table 1 Recommendations for management of hepatorenal syndrome AKI: acute kidney injury; CKD: chronic kidney disease; CVP: central venous pressure; HRS: hepatorenal syndrome; ICU: intensive care unit; LT: liver transplantation; NAKI: non-acute kidney Injury; RRT: renal replacement therapy; SBP: spontaneous bacterial peritonitis; SCr: serum creatinine; TIPS: transjugular intrahepatic portosystemic shunt.
Literature index: Simonetto DA, Gines P, Kamath PS.
Hepatorenal syndrome: pathophysiology, diagnosis, and management.
BMJ.
2020 09 14;370.
doi: 10.
1136/bmj.
m2687.
●The most complete summary: Diagnosis and diagnosis of hepatorenal syndrome Treatment|Clinical Essentials ●Hepatorenal Syndrome: Why can kidney failure be caused by the absence of kidney disease?